Dr. Alison Schram, MD

• Medical Oncology

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Memorial Sloan-kettering Cancer Center

  Fellowship Hospital, 2018

• Brigham And Womens Hospital

  Residency Hospital, 2015

• Brigham And Womens Hospital

  Internship Hospital, 2013

• University Of Pennsylvania Perelman School Of Medicine

  Medical School, 2012

• TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors, 2020-10-01

• High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden, 2019-04-26

• Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance, 2017-08-31

• A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours, 2018-11-14

• Towards a more precise future for oncology, 2020-04-13

• A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors, 2017-06-03

• Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements, 2022-05-02

• AKT mutant allele-specific activation dictates pharmacologic sensitivities, 2022-04-19

• Colorectal carcinomas containing hypermethylated MLH1 promoter and wild type BRAF/KRAS are enriched for targetable kinase fusions, 2019-01-14

• Widespread selection for oncogenic mutant allele imbalance in cancer, 2018-11-01

• Discovery through clinical sequencing in oncology, 2020-08-10

• Accelerating discovery of functional mutant alleles in cancer, 2017-12-15

• Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation, 2019-08-12

• HER kinase inhibition in patients with HER2- and HER3-mutant cancers, 2018-01-31

• Reversion mutations in germlineBRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies, 2022-11-23

• Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology, 2019-07-24

• Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes, 2017-04-26

• Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology, 2017-11-09

• Quantifying the Benefits of Genome-Driven Oncology, 2017-04-28

• A germlineJAK2SNP is associated with predisposition to the development ofJAK2V617F-positive myeloproliferative neoplasms, 2009-03-15

• Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer, 2016-10-26

• Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes, 2021-05-04

• Genome doubling shapes the evolution and prognosis of advanced cancers, 2018-07-16

• Selective AKT kinase inhibitor capivasertib in combination with fulvestrant inPTEN-mutant ER-positive metastatic breast cancer, 2021-04-16

• Clinical implications of drug-induced liver injury on early-phase oncology clinical trials, 2020-08-18

• Precision oncology: Charting a path forward to broader deployment of genomic profiling, 2017-02-21

• Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors, 2019-05-16

• Efficacy and Determinants of Response to HER Kinase Inhibition inHER2-Mutant Metastatic Breast Cancer, 2019-12-05